S
Suhas Singla
Researcher at All India Institute of Medical Sciences
Publications - 35
Citations - 307
Suhas Singla is an academic researcher from All India Institute of Medical Sciences. The author has contributed to research in topics: Metastasis & Radioimmunotherapy. The author has an hindex of 8, co-authored 34 publications receiving 267 citations.
Papers
More filters
Journal ArticleDOI
177 Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study
TL;DR: 177Lu-EDTMP was found to be a safe and effective radiopharmaceutical for bone pain palliation in patients with metastatic prostate and breast carcinoma and there were no differences in efficacy or toxicity between patients receiving low-dose and high-dose 177Lu- EDTMP.
Journal ArticleDOI
Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
TL;DR: The decline in renal function as measured by in vitro GFR tends to be of greater magnitude in patients with baseline impaired renal function than in Patients with preserved renal function after PRRT.
Journal ArticleDOI
Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
TL;DR: The maximum cumulative activity of 177Lu-DOTATATE that can be safely administered to a patient within permissible renal threshold in the authors' study was found to be 40 GBq (1100 mCi), however, there are considerable interpatient differences in absorbed doses of all organs requiring individualized dosimetry for optimizing tumor dose.
Journal ArticleDOI
Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Sellam Karunanithi,Guru Bandopadhyaya,Punit Sharma,Abhishek Kumar,Suhas Singla,Arun Malhotra,Deepak Gupta,Chandrasekhar Bal +7 more
TL;DR: For detection of recurrence in glioma patients, 99mTc-GH SPECT/CT is not inferior to 18F-FDOPA PET/CT and can be used as a low-cost alternative.
Journal Article
An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Parul Thakral,Suhas Singla,Madhav Prasad Yadav,Atul Vasisht,Atul Sharma,Santosh Gupta,Chandrashekhar Bal,Snehlata,Arun Malhotra +8 more
TL;DR: A favourable radiochemical purity, stability and biodistribution of the radiolabelled immunoconjugate indicate that clinical trials for evaluation of toxicity and efficacy of 177Lu-DOTA-antiCD20 antibody-Rituximab (BioSim) in patients of relapsed and refractory non Hodgkin's lymphoma can be considered.